Finance

Lists
Q3 2026 earnings • released • EPS beat +6.88% • Revenue beat +0.63%
See results
KRYS:NASDAQ
Krystal Biotech Inc
$295.90
-10.95%
(-36.39) 1D
$295.00
-0.30% (-0.90)
After hours
Closed: Nov 2, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KRYS...
Open
$314.21
High
$317.00
Low
$281.40
Mkt. cap
8.76B
Avg. vol.
262.18K
Volume
1.20M
P/E ratio
37.10
52-wk high
$382.54
52-wk low
$184.02
EPS
$7.98
Beta
0.50
Shares outstanding
29.60M
No. of employees
295
Open
$314.21
High
$317.00
Low
$281.40
Mkt. cap
8.76B
Avg. vol.
262.18K
Volume
1.20M
P/E ratio
37.10
52-wk high
$382.54
52-wk low
$184.02
EPS
$7.98
Beta
0.50
Shares outstanding
29.60M
No. of employees
295
News stories
From web sources and news partners
About Krystal Biotech Inc
CEO-
Employees295
Founded2016
HeadquartersPittsburgh, Pennsylvania, United States
SectorBiotechnology
Websitekrystalbio.com
Analyst ratings
Based on 8 analysts giving stock ratings to KRYS in the past 3 months
Strong buy
Buy
7
Hold
1
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for KRYS in the last 3 months.
Highest
Current $295.90
$441.00 (+49.04%)
Average
$403.50 (+36.36%)
Lowest
$361.00 (+22.00%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yigal Nochomovitz
Citi
Buy
Reiterated
$412.00
+39.2%
11/02/2026
Alec Stranahan
Bank of America Securities
Buy
Reiterated
$390.00
+31.8%
11/02/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$361.00
+22%
11/02/2026
Lisa Walter
RBC Capital
Buy
Reiterated
$400.00
+35.2%
11/02/2026
Ritu Baral
TD Cowen
Buy
Maintained
$403.00
+36.2%
10/21/2026
Andrea Newkirk
Goldman Sachs
Buy
Initiated
$441.00
+49%
09/24/2026
Unknown Analyst
RBC Capital
Buy
Initiated
$400.00
+35.2%
08/14/2026
Kalpit Patel
Wolfe Research
Hold
Maintained
-
-
08/11/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/03/2026
Roger Song
Jefferies
Buy
Reiterated
$474.00
+60.2%
07/13/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Maintained
$300.00
+1.4%
05/05/2026
Debjit Chattopadhyay
Guggenheim
Buy
Reiterated
$284.00
-4%
05/04/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
$323.00
+9.2%
05/04/2026
William Maughan
Clear Street
Buy
Maintained
$311.00
+5.1%
05/04/2026
Andrea Tan
Goldman Sachs
Buy
Reiterated
$327.00
+10.5%
01/30/2026
Last report
Just released
Today, 8:30 AM
Fiscal period
Q3 2026
$2.05 / $1.92
+6.88%beat
Revenue / Est. (USD)
127.34M / 126.54M
+0.63%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
97.80M
107.10M
116.36M
119.22M
Cost of goods sold
4.26M
6.59M
6.32M
6.44M
Cost of revenue
4.26M
6.59M
6.32M
6.44M
Research and development expenses
14.58M
14.79M
15.33M
14.52M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
37.58M
41.45M
41.01M
39.85M
Operating expense
52.16M
56.24M
56.34M
54.37M
Total operating expenses
56.43M
62.84M
62.67M
60.80M
Operating income
41.37M
44.27M
53.69M
58.42M
Other non operating income
-
-
-
-
EBT including unusual items
47.97M
51.13M
61.44M
66.08M
EBT excluding unusual items
47.97M
51.13M
61.44M
66.08M
Income tax expense
-31.40M
-269.00K
5.51M
11.31M
Effective tax rate
-65.46%
-0.53%
8.97%
17.12%
Other operating expenses
-
-
-
-
Net income
79.36M
51.40M
55.93M
54.77M
Net profit margin
81.15%
47.99%
48.07%
45.94%
Earnings per share
2.66
1.70
1.83
1.79
Interest and investment income
6.59M
6.86M
7.75M
7.66M
Interest expense
-
-
-
-
Net interest expenses
6.59M
6.86M
7.75M
7.66M
Depreciation and amortization charges
-
-
-
-
EBITDA
41.68M
44.83M
54.21M
58.57M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps